Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02769780
Recruitment Status : Active, not recruiting
First Posted : May 12, 2016
Last Update Posted : September 28, 2021
Sponsor:
Collaborators:
Invitae
Wake Up Narcolepsy
Narcolepsy Network
ICON plc
Information provided by (Responsible Party):
Jazz Pharmaceuticals

Brief Summary:

Nexus is a collaboration between academic institutions, advocacy and industry to answer important questions about narcolepsy. It is a web-based observational study of patient-reported outcomes in adult patients with narcolepsy, with follow-up every six months.

Nexus website: www.narcolepsyregistry.com


Condition or disease
Narcolepsy

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 1500 participants
Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration: 6 Months
Official Title: A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy
Actual Study Start Date : July 8, 2015
Estimated Primary Completion Date : December 15, 2021
Estimated Study Completion Date : December 15, 2021

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Descriptive epidemiology of type 1 and type 2 narcolepsy [ Time Frame: Participants complete a survey every 6 months for 3 years after enrollment ]
    Assessments include disease/diagnosis characteristics, disease/symptom characteristics, health-related quality of life (HRQoL), functioning, work productivity, resource utilization, and comorbidity burden at the time of enrollment and their progression through the course of the study


Secondary Outcome Measures :
  1. Medication utilization and treatment outcomes for type 1 and type 2 narcolepsy [ Time Frame: Participants complete a survey every 6 months for 3 years after enrollment ]
    Assessments include: Medication use, non-pharmacologic disease management, symptom relief, quality of life (QoL), functionality and productivity associated with varying treatment regimens at baseline and their change throughout the course of the study



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All adult patients with narcolepsy
Criteria

Inclusion Criteria:

  • 18 years or older
  • Diagnosed with narcolepsy by a doctor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02769780


Locations
Layout table for location information
United States, California
Jazz Pharmaceuticals
Palo Alto, California, United States, 94304
Sponsors and Collaborators
Jazz Pharmaceuticals
Invitae
Wake Up Narcolepsy
Narcolepsy Network
ICON plc
Investigators
Layout table for investigator information
Study Director: Danielle Hyman, PhD Jazz Pharmaceuticals
Principal Investigator: JeanPierre Coaquira, MPH Jazz Pharmaceuticals
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jazz Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02769780    
Other Study ID Numbers: Nexus Narcolepsy Registry
First Posted: May 12, 2016    Key Record Dates
Last Update Posted: September 28, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Narcolepsy
Disorders of Excessive Somnolence
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders